KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $7.6 million.

  • Alnylam Pharmaceuticals' Other Non-Current Liabilities fell 9844.04% to $7.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.6 million, marking a year-over-year decrease of 9844.04%. This contributed to the annual value of $7.6 million for FY2025, which is 9844.04% down from last year.
  • Alnylam Pharmaceuticals' Other Non-Current Liabilities amounted to $7.6 million in Q4 2025, which was down 9844.04% from $439.7 million recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Other Non-Current Liabilities peaked at $486.9 million during Q4 2024, and registered a low of $7.6 million during Q4 2025.
  • In the last 5 years, Alnylam Pharmaceuticals' Other Non-Current Liabilities had a median value of $240.6 million in 2023 and averaged $242.2 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Other Non-Current Liabilities soared by 55732.77% in 2021, and later crashed by 9844.04% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Other Non-Current Liabilities stood at $99.0 million in 2021, then soared by 114.81% to $212.6 million in 2022, then soared by 45.09% to $308.4 million in 2023, then surged by 57.87% to $486.9 million in 2024, then tumbled by 98.44% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q4 2025, $439.7 million for Q3 2025, and $407.5 million during Q2 2025.